Matches in SemOpenAlex for { <https://semopenalex.org/work/W2416716506> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2416716506 endingPage "44" @default.
- W2416716506 startingPage "S39" @default.
- W2416716506 abstract "Up to 80% of children with acute myelogenous leukemia treated with intensive chemotherapy achieve remission; however, a large proportion of patients develops recurrent disease. Because interleukin (IL)-2 can induce remission in patients with overt evidence of acute myelogenous leukemia, we hypothesized that it might prevent relapse when administered to patients in first remission after intensive consolidation chemotherapy. A pilot Children's Cancer Group (CCG) trial (CCG-0941) demonstrated the feasibility of this approach, and we initiated a prospective randomized trial (CCG-2961) to further evaluate the safety and potential efficacy of IL-2 therapy in preventing relapse of acute myelogenous leukemia.In trial CCG-0941, 21 pediatric patients in complete remission following induction and consolidation chemotherapy on protocol CCG-2941 received IL-2 therapy. In CCG-2961, 79 patients in complete remission were randomized as of February 1999 to receive either IL-2 (n = 39) or no further therapy. In both trials, recombinant IL-2 was given at a dose of 9 million IU/m2/d by continuous intravenous infusion for 4 days. After 4 days of rest, IL-2 was resumed at a dose of 1.6 million IU/m2/d for 10 days by continuous infusion. We monitored patients for toxicity and relapse.The majority of patients treated with IL-2 in these two trials experienced some degree of fever. Seven of 60 patients (12%) had clinically significant rashes, and grade 3 vascular leak syndrome and hypotension have each been observed in five patients (8%). Hypotension resolved promptly after treatment with intravenous fluids. No patients have experienced renal toxicity or required cardiac vasopressors or transfer to an intensive care unit; there have been no treatment-related deaths. Overall, the incidence and severity of adverse events remain similar in the two trials. Total projected accrual to the IL-2 randomization is anticipated to be 326 patients, and relapse and survival data remain blinded.The dose and schedule of IL-2 used in these two trials continue to be reasonably well tolerated by children with acute myelogenous leukemia in first remission. Any conclusions with regard to efficacy must await completion of the randomized trial." @default.
- W2416716506 created "2016-06-24" @default.
- W2416716506 creator A5011786310 @default.
- W2416716506 creator A5012681561 @default.
- W2416716506 creator A5025268461 @default.
- W2416716506 creator A5027933135 @default.
- W2416716506 creator A5044829454 @default.
- W2416716506 creator A5053189530 @default.
- W2416716506 creator A5088274260 @default.
- W2416716506 creator A5088877199 @default.
- W2416716506 date "2000-02-01" @default.
- W2416716506 modified "2023-10-01" @default.
- W2416716506 title "Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia." @default.
- W2416716506 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10685657" @default.
- W2416716506 hasPublicationYear "2000" @default.
- W2416716506 type Work @default.
- W2416716506 sameAs 2416716506 @default.
- W2416716506 citedByCount "5" @default.
- W2416716506 countsByYear W24167165062018 @default.
- W2416716506 countsByYear W24167165062022 @default.
- W2416716506 crossrefType "journal-article" @default.
- W2416716506 hasAuthorship W2416716506A5011786310 @default.
- W2416716506 hasAuthorship W2416716506A5012681561 @default.
- W2416716506 hasAuthorship W2416716506A5025268461 @default.
- W2416716506 hasAuthorship W2416716506A5027933135 @default.
- W2416716506 hasAuthorship W2416716506A5044829454 @default.
- W2416716506 hasAuthorship W2416716506A5053189530 @default.
- W2416716506 hasAuthorship W2416716506A5088274260 @default.
- W2416716506 hasAuthorship W2416716506A5088877199 @default.
- W2416716506 hasConcept C121608353 @default.
- W2416716506 hasConcept C126322002 @default.
- W2416716506 hasConcept C141071460 @default.
- W2416716506 hasConcept C143998085 @default.
- W2416716506 hasConcept C168563851 @default.
- W2416716506 hasConcept C2776694085 @default.
- W2416716506 hasConcept C2778041864 @default.
- W2416716506 hasConcept C2778461978 @default.
- W2416716506 hasConcept C535046627 @default.
- W2416716506 hasConcept C71924100 @default.
- W2416716506 hasConcept C90924648 @default.
- W2416716506 hasConceptScore W2416716506C121608353 @default.
- W2416716506 hasConceptScore W2416716506C126322002 @default.
- W2416716506 hasConceptScore W2416716506C141071460 @default.
- W2416716506 hasConceptScore W2416716506C143998085 @default.
- W2416716506 hasConceptScore W2416716506C168563851 @default.
- W2416716506 hasConceptScore W2416716506C2776694085 @default.
- W2416716506 hasConceptScore W2416716506C2778041864 @default.
- W2416716506 hasConceptScore W2416716506C2778461978 @default.
- W2416716506 hasConceptScore W2416716506C535046627 @default.
- W2416716506 hasConceptScore W2416716506C71924100 @default.
- W2416716506 hasConceptScore W2416716506C90924648 @default.
- W2416716506 hasLocation W24167165061 @default.
- W2416716506 hasOpenAccess W2416716506 @default.
- W2416716506 hasPrimaryLocation W24167165061 @default.
- W2416716506 hasRelatedWork W1583871986 @default.
- W2416716506 hasRelatedWork W2033096478 @default.
- W2416716506 hasRelatedWork W2073730465 @default.
- W2416716506 hasRelatedWork W2142097265 @default.
- W2416716506 hasRelatedWork W2358739720 @default.
- W2416716506 hasRelatedWork W2409051292 @default.
- W2416716506 hasRelatedWork W2414858770 @default.
- W2416716506 hasRelatedWork W2444412112 @default.
- W2416716506 hasRelatedWork W3009124764 @default.
- W2416716506 hasRelatedWork W2413788036 @default.
- W2416716506 hasVolume "6 Suppl 1" @default.
- W2416716506 isParatext "false" @default.
- W2416716506 isRetracted "false" @default.
- W2416716506 magId "2416716506" @default.
- W2416716506 workType "article" @default.